Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792901

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792901

Wilms Tumor Treatment

PUBLISHED:
PAGES: 373 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Wilms Tumor Treatment Market to Reach US$1.8 Billion by 2030

The global market for Wilms Tumor Treatment estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Favorable Histology Type, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Anaplastic Histology Type segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$409.7 Million While China is Forecast to Grow at 5.5% CAGR

The Wilms Tumor Treatment market in the U.S. is estimated at US$409.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$348.5 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Wilms Tumor Treatment Market - Key Trends & Drivers Summarized

Why Is Wilms Tumor Treatment a Priority in Advancing Pediatric Oncology Outcomes Worldwide?

Wilms tumor treatment has become a focal point in the realm of pediatric oncology due to its prevalence among young children and its high potential for cure when diagnosed and managed early. Wilms tumor, also known as nephroblastoma, is the most common type of kidney cancer in children, typically affecting those under the age of five. Given its critical location and tendency to grow rapidly, prompt and targeted treatment is essential for improving survival rates and preserving kidney function. The current standard of care involves a combination of surgery, chemotherapy, and in some cases, radiation therapy. Surgical removal of the tumor-bearing kidney is often the first step, followed by adjuvant therapies to eliminate any residual cancer cells and prevent recurrence. The success of Wilms tumor treatment has improved significantly over the past few decades, with survival rates exceeding 90 percent in early-stage cases due to advances in multimodal approaches and risk stratification protocols. However, the condition’s rarity and the need for highly specialized care underscore the importance of early detection, centralized treatment planning, and coordinated multidisciplinary teams. Awareness campaigns, regular pediatric check-ups, and advancements in diagnostic imaging have also contributed to earlier diagnosis, which is key to favorable outcomes. Ensuring access to quality treatment across socioeconomic and geographic boundaries remains a global health priority, especially in low- and middle-income countries where delayed diagnosis and limited treatment infrastructure can significantly impact survival rates.

How Are Technological and Scientific Advancements Enhancing Wilms Tumor Diagnosis and Therapy?

Recent scientific and technological advancements are transforming the diagnosis and treatment of Wilms tumor, enabling more precise, effective, and individualized care strategies. Imaging modalities such as ultrasound, MRI, and CT scans are improving tumor detection and staging accuracy, helping clinicians differentiate between localized and metastatic disease with greater confidence. Molecular diagnostics and genetic testing are playing an increasingly important role in risk assessment, allowing oncologists to classify patients based on tumor histology and genetic markers such as WT1 mutations or loss of heterozygosity at specific chromosome loci. These insights guide treatment intensity, helping to avoid over-treatment in low-risk patients while ensuring aggressive management for high-risk cases. Innovations in surgical techniques, including minimally invasive approaches, are reducing recovery times and preserving kidney function in select cases. On the pharmaceutical front, new chemotherapeutic agents and refined dosing regimens are improving treatment efficacy while minimizing toxicity. Researchers are also exploring the use of targeted therapies and immunotherapies, particularly in relapsed or refractory Wilms tumor cases, though these are still largely in the experimental stages. Radiotherapy techniques have also evolved, with conformal and intensity-modulated radiotherapy allowing for greater precision and less damage to surrounding tissues. Moreover, advancements in supportive care, such as better antiemetics, infection control, and nutritional support, are enhancing the overall treatment experience for young patients. These collective innovations are not only improving survival outcomes but also reducing long-term treatment-related complications, which is crucial for the quality of life in pediatric cancer survivors.

What Patient Needs and Healthcare Trends Are Influencing the Evolution of Wilms Tumor Treatment?

The evolution of Wilms tumor treatment is being increasingly shaped by patient-centered care models, emerging healthcare trends, and the growing emphasis on survivorship and long-term quality of life. As pediatric cancer survival rates improve, attention is turning toward minimizing the physical, cognitive, and psychosocial effects of treatment. Families and caregivers are demanding therapies that not only cure but also preserve future health, including fertility, organ function, and cognitive development. This has led to a greater focus on treatment de-escalation for low-risk patients, reducing exposure to aggressive chemoradiotherapy while still maintaining cure rates. Another important trend is the rise of multidisciplinary care teams that include pediatric oncologists, nephrologists, surgeons, psychologists, nutritionists, and social workers, ensuring comprehensive and holistic treatment planning. Patient advocacy groups and nonprofit organizations are playing a critical role in driving awareness, funding research, and offering support to affected families. Telemedicine and digital health platforms are becoming essential in follow-up care and patient monitoring, particularly in remote or underserved areas where specialized oncology services may be limited. Additionally, clinical trials are being redesigned to be more inclusive and adaptive, allowing for faster evaluation of novel therapies and broader participation among diverse populations. Insurance coverage and healthcare policy are also evolving to support early screening, genetic counseling, and long-term survivorship programs. These developments are empowering patients and families to take a more active role in care decisions, while encouraging healthcare providers to deliver personalized, compassionate, and forward-looking treatment strategies.

What Is Driving the Global Expansion and Advancement of Wilms Tumor Treatment Options?

The growth in the Wilms tumor treatment market is driven by a convergence of medical innovation, institutional collaboration, improved diagnostics, and increasing global commitment to pediatric oncology. Investment in pediatric cancer research is growing steadily, with governments, academic institutions, and private organizations prioritizing the development of safer, more effective treatments tailored specifically to children. The success of international cooperative groups such as the Children’s Oncology Group (COG) and the International Society of Pediatric Oncology (SIOP) has been instrumental in setting global standards of care and conducting large-scale clinical trials that inform evidence-based treatment protocols. Public-private partnerships are accelerating access to life-saving drugs and technologies in both high-income and resource-constrained regions. In many countries, national cancer control plans are beginning to include dedicated pediatric oncology components, providing funding for diagnostic infrastructure, healthcare workforce training, and drug procurement. Increasing awareness about childhood cancer, coupled with advocacy from patient groups, is helping to reduce stigma and promote early detection, which is critical for Wilms tumor outcomes. Technological improvements in data analytics, genomic sequencing, and health information systems are enabling more accurate patient stratification and treatment personalization. Furthermore, the integration of survivorship care plans into oncology practice is enhancing the long-term monitoring and support of Wilms tumor survivors, ensuring they receive ongoing care for late effects of treatment. These multidimensional efforts are collectively driving the global expansion of Wilms tumor treatment options, fostering a healthcare environment where early detection, effective therapy, and long-term well-being are achievable for children regardless of geography or socioeconomic status.

SCOPE OF STUDY:

The report analyzes the Wilms Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Favorable Histology Type, Anaplastic Histology Type); Treatment (Surgery, Chemotherapy, Radiation Therapy, Other Treatments); End-Use (Hospitals End-Use, Cancer Research Centers End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Astellas Pharma
  • Atara Biotherapeutics
  • BioInvent International
  • CureVac (now part of Inex)
  • GlaxoSmithKline (GSK)
  • Inex Pharmaceuticals
  • Inovio Pharmaceuticals
  • Intellia Therapeutics
  • Medigene
  • Merck & Co.
  • Novartis
  • Pfizer
  • Plus Therapeutics
  • Roche
  • Sellas Life Sciences Group
  • The University of Texas MD Anderson
  • TranScripTx (GeneTx)
  • Verastem Oncology
  • Washington University St. Louis

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38391

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Wilms Tumor Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Improved Survival Outcomes Throw the Spotlight on Advancements in Multimodal Wilms Tumor Treatment Protocols
    • Rising Incidence of Pediatric Renal Tumors Spurs Demand for Early Diagnosis and Targeted Therapeutic Approaches
    • Refinement of Risk Stratification Guidelines Propels Growth of Personalized Chemotherapy Regimens
    • Here's How Advances in Pediatric Oncology Are Enhancing Surgical Precision and Organ Preservation Strategies
    • Expanding Role of Radiotherapy in High-Risk and Recurrent Cases Strengthens the Business Case for Proton and IMRT Solutions
    • Research in Molecular and Genetic Markers Expands the Addressable Opportunity for Precision Medicine in Wilms Tumor
    • Availability of Targeted Therapies and Monoclonal Antibodies Generates Hope for Refractory and Relapsed Patients
    • Here's How Fertility and Long-Term Toxicity Concerns Are Driving Demand for Less Invasive Treatment Options
    • Improvements in Imaging and Preoperative Staging Drive Early Intervention and Risk-Adapted Treatment Planning
    • Pharmaceutical Advances in Pediatric Formulations Sustain Growth in Age-Specific Drug Delivery Systems
    • Access to Specialized Pediatric Cancer Centers Creates Regional Disparities and Opportunities for Outreach Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Wilms Tumor Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Wilms Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Wilms Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Favorable Histology Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Favorable Histology Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Favorable Histology Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anaplastic Histology Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anaplastic Histology Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anaplastic Histology Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cancer Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cancer Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • JAPAN
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • CHINA
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • EUROPE
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Wilms Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Wilms Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • FRANCE
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • GERMANY
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Wilms Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • INDIA
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Wilms Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Wilms Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Wilms Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Wilms Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030
  • AFRICA
    • Wilms Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Wilms Tumor Treatment by Type - Favorable Histology Type and Anaplastic Histology Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Wilms Tumor Treatment by Type - Percentage Breakdown of Value Sales for Favorable Histology Type and Anaplastic Histology Type for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Wilms Tumor Treatment by End-Use - Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Wilms Tumor Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Cancer Research Centers End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Wilms Tumor Treatment by Treatment - Surgery, Chemotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Wilms Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy and Other Treatments for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!